Liposomal Bupivacaine for Pain After Lumbar Fusion

PHASE4RecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Postoperative Acute PainLumbar Degenerative Diseases
Interventions
DRUG

Liposomal bupivacaine (local infiltration)

"Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg bupivacaine hydrochloride (10 mL total volume). The drug will be injected bilateral into the paraspinal muscles and subcutaneous tissues prior to wound closure. This provides both immediate (bupivacaine HCl) and prolonged (liposomal) analgesia."

DRUG

ropivacaine (local infiltration)

Patients will receive 120 mg ropivacaine diluted to 30 mL (single-level) or 40 mL (two-level) with normal saline. The solution will be infiltrated bilateral into the paraspinal muscles and subcutaneous tissues using the same technique as the experimental arm, ensuring consistent injection depth and distribution.

Trial Locations (1)

Unknown

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Min Li

OTHER